Estrella Immunopharma Inc (ESLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.65+0.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ESLA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ESLA — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Dated 2026-08-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share for 30 consecutive business days from July 6,…
Why it matters: A drop in revenue growth signals weakening demand in a decelerating sector. This could hurt Estrella's position.
Worry ifRevenue growth falls below the median for the health care sector.
Less concerning ifRevenue growth stays above the median for the health care sector.
Why it matters: Legal responses to the Nasdaq notice will impact the company's compliance efforts and stock price.
Worry ifThe company shares a press release about a successful appeal or compliance plan.
Less concerning ifThere are no updates or bad news about the Nasdaq compliance issue.
Why it matters: Ongoing losses show financial problems. The company needs to improve to gain investor trust.
Supportive ifOperating income shows a reduction in losses, improving to less than -$2.00M.
Worry ifOperating income is still negative and gets worse beyond -$2.08M.
Why it matters: The company is at risk of being delisted. A compliance update is crucial.
Worry ifThe company announced it meets Nasdaq listing rules.
Less concerning ifA notice about delisting or not meeting compliance rules.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$236 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $1,052 loss on $10,000 · 10.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,898 loss on $10,000 · 79.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If revenue growth in the health care sector speeds up, it could benefit Estrella Immunopharma. A stronger sector can lift all companies within it.
Supportive ifSector revenue growth speeds up to over 9% year over year.
Worry ifSector revenue growth remains below 9% year over year.
Why it matters: The company faces delisting risk due to its stock price below $1.00. Progress is crucial for maintaining its Nasdaq listing.
Worry ifStock price closes above $1.00 for 10 consecutive business days.
Less concerning ifThe stock price stays below $1.00 for 30 straight business days.